Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	10.33M 9.03M 8.33M 7.66M 14.51M 994M 14.75M 99.42M 39.01M 486M 38.78M 37.93M 1.67B	P/E 2024	-2.88x	P/E 2025	-6.9x
Enterprise Value	6.76M 5.91M 5.45M 5.01M 9.49M 650M 9.65M 65.05M 25.52M 318M 25.37M 24.81M 1.1B	EV / Sales 2024	70.2x	EV / Sales 2025	-
Free-Float	67.19%	Yield 2024 *	-	Yield 2025	-

01/07	Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026	CI
30/05	Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/04	Exicure announces co-development agreement with Adbiotech for burixafor (GPC-100)	RE
23/04	Exicure, Inc. And Adbiotech Co., Ltd. Enter Co-Development Agreement For Burixafor (GPC-100)	CI
11/04	Exicure, Inc. Announces Management Changes	CI
28/03	Exicure, Inc. Announces Resignation of Director Sangjin Yeo from Board and Audit Committee, Effective March 27, 2026	CI
26/03	Exicure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25/03	Exicure, Inc. Auditor Raises 'Going Concern' Doubt	CI
18/02	Exicure appoints Jung Soo Kim as CEO and president	RE
18/02	Exicure, Inc. Announces Executive Appointments, Effective February 11, 2026	CI
18/02	Exicure, Inc. Appoints Gyuyeob Lee as Interim Chief Financial Officer, Effective February 11, 2026	CI
18/02	Exicure, Inc. Appoints Jung Soo Kim as Chief Executive Officer, Effective February 11, 2026	CI
11/02	Exicure, Inc. Announces Resignation of Seung Ik Baik as Chief Financial Officer, Effective February 9, 2026	CI

17/08/22	Chardan Adjusts Exicure's Price Target to $2 on 1-for-30 Reverse Stock Split, Maintains Neutral Rating	MT
29/03/22	Chardan Adjusts Exicure's Price Target to $0.25 From $0.40 'on Increased Dilution;' Neutral Rating Kept	MT
14/12/21	Chardan Downgrades Exicure to Neutral From Buy After Probe Shows Clinical Data Misrepresentation, Lowers PT to $0.40 From $2.25	MT
24/11/21	Chardan Adjusts Price Target on Exicure to $2.25 From $7 'on Uncertain Delays for Clinical Programs,' Keeps Buy Rating	MT
17/05/21	EXICURE : HC Wainwright Adjusts Price Target on Exicure to $6 From $8, Maintains Buy Rating	MT

30/06	Exicure Announces Board and Committee Changes	AQ
11/06	Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement	AQ
02/06	Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q	AQ
23/04	Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)	AQ
03/04	Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions	AQ

02/08/21	Les valeurs à suivre aujourd'hui à Paris Lundi 2 août 2021
02/08/21	Ipsen : signe un partenariat avec Exicure dans les acides nucléiques sphériques
02/08/21	EN DIRECT DES MARCHES : Axa, Bolloré, Neoen, Ipsen, HSBC, Heineken, Square, Moderna...
02/08/21	Ipsen : accord de collaboration avec Exicure
02/08/21	Dernière ligne droite avant la coupure aoûtienne

Exicure Inc Stock Other OTC

Stocks

US30205M1018

Biotechnology & Medical Research

Valuation: Exicure Inc

Latest news : Exicure Inc

Analysts' recommendations: Exicure Inc

Press Releases: Exicure Inc

News in other languages: Exicure Inc

Quotes and Performance

Managers and Directors: Exicure Inc

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Jungsoo Kim CEO	Chief Executive Officer	-	11/02/2026
Josephine Cardarelli PSD	President	-	06/10/2025
Gyuyeob Lee DFI	Director of Finance/CFO	40	11/02/2026

Director	Title	Age	Since
Dong-Ho Lee BRD	Director/Board Member	64	21/08/2023
Jungsoo Kim BRD	Director/Board Member	-	11/02/2026
Gyeung Seog Cheon BRD	Director/Board Member	-	09/02/2026

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXICURE INC	+0.76%	+20.45%	-	-	10.33M
WUXI APPTEC CO., LTD.	+3.13%	+13.95%	+64.21%	+94.35%	57.82B
ARGENX SE	-1.39%	-6.15%	+56.05%	+124.73%	53.71B
INSMED INCORPORATED	-0.27%	-5.77%	+6.75%	+433.06%	23.8B
BIONTECH SE	+1.76%	-1.65%	-16.86%	-15.01%	23.26B
WUXI BIOLOGICS (CAYMAN) INC.	0.00%	+6.85%	+45.59%	-3.06%	20.7B
GENMAB A/S	+1.94%	+0.21%	+39.31%	-27.77%	17.81B
PHARMAESSENTIA CORPORATION	+10.00%	-4.30%	+208.33%	+370.99%	16.9B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.80%	+9.89%	+46.88%	+698.78%	16.36B
EXELIXIS, INC.	-0.39%	-1.00%	+26.08%	+186.49%	13.96B
Average	+1.30%	+1.42%	+52.93%	+206.95%	27.15B
Weighted average by Cap.	+1.22%	+1.35%	+52.33%	+171.32%

	2024	2025
Net sales	500K 437K 403K 371K 702K 48.11M 714K 4.81M 1.89M 23.52M 1.88M 1.84M 81.05M	-
Net income	-9.7M -8.48M -7.82M -7.19M -13.63M -933M -13.86M -93.41M -36.65M -456M -36.43M -35.63M -1.57B	-4.95M -4.32M -3.99M -3.67M -6.95M -476M -7.07M -47.62M -18.69M -233M -18.57M -18.17M -802M
Net Debt	-6.46M -5.65M -5.21M -4.79M -9.08M -622M -9.24M -62.24M -24.42M -304M -24.27M -23.74M -1.05B	-3.57M -3.12M -2.88M -2.65M -5.02M -344M -5.1M -34.37M -13.49M -168M -13.41M -13.11M -579M